A nation-wide evaluation of dopamine usage in New Zealand Intensive Care Units (ICUs) was undertaken. Twenty-six public hospital ICUs participated. Twenty-two ICUs (85%) use dopamine as an inotrope. Seventeen ICUs use dopamine for presumed selective renal effects at least occasionally, but with wide variation in what is considered to be "renal-dose". Level 3 ICUs were less likely to use "renal-dose" dopamine than levels 1 and 2 (P=0.01). Nineteen units (83%) use weight-referenced (i.e., µg.kg -1 .min -1 ) dopamine administration. Weight-referenced administration and "renal-dose" dopamine were likely to be in use together (P=0.02). Standard dopamine dilutions varied widely with a median of 2 mg.ml -1 (range 0.4 to 8 mg.ml -1 ). Given a demonstrated association between weight-referenced administration and "renal-dose" dopamine, along with particular pharmacokinetic and pharmacodynamic reservations, the value of weight-referenced administration of dopamine in adult patients is questioned.
Dopamine is used as a first-choice inotrope in adults within the Intensive Care Unit (ICU) at Palmerston North Hospital, New Zealand. It is current practice to prescribe and administer it as an absolute amount per unit time (i.e., mg.h -1 , or ml.h -1 of a standard concentration) rather than as a weight-referenced amount per unit time (i.e., µg.kg -1 .min -1 ). A nation-wide evaluation of dopamine usage has been undertaken with the intention of describing aspects of current practice of dopamine administration throughout New Zealand (NZ). This specifically included identifying the prevalence of dopamine usage as an inotrope and/or as a selective renal agent, standard dilutions and the way in which dopamine is prescribed and administered on a day-today basis, with particular regard to weight-referenced regimens.
METHODS
Using a mailing list obtained from the NZ national committee of ANZICS, 26 NZ public hospital Intensive Care Units were identified, and each telephoned during the course of the same after-noon. A brief structured questionnaire concerning dopamine usage was administered. It was intended that the questionnaire be administered to the duty registrar. In units without registrars (or where the specialist answered the phone), the questions were asked of the duty specialist if she or he was immediately available in the unit. In all other cases, the nurse-in-charge provided answers to the questions. The level of each ICU was determined from the mailing list, together with information contained within the ANZICS Intensive Care Survey 1 .
Statistical analysis was performed using the SPSS software package (SPSS 10.0.7; SPSS Inc., Chicago, IL). Differences between groups were examined using Kruskall-Wallis. A P<0.05 was considered significant.
RESULTS
All 26 ICUs participated. Ten specialists, six registrars and 10 senior nurses responded.
Twenty-two units (85%) use dopamine as an inotrope. Two respondents spontaneously advised that dopamine is only infrequently used, usually to temporize whilst other agents (e.g., noradrenaline) are organized. One other unit only ever uses dopamine in low-dose on occasion for its presumed renal effects. The other three units stated that dopamine is not used at all (see Table 1 ). There was no statistically significant relationship between the ICU level and use of dopamine (P>0.05).
In six (26%) of these ICUs, dopamine is reportedly never used for any potential selective renal effects. Three units (13%) advised that use of "renal-dose" dopamine is considered routine, with the remaining 14 (61%) using low-dose dopamine on some occasions for its putative renal effects (variously prophylactically or therapeutically). Level 3 ICUs that use dopamine were less likely to use it for any renal effect than levels 1 and 2 (P=0.01). Differing dose ranges were quoted as "renal-dose" (see Table 2 ).
Routine dilution of dopamine ranges from 0.4 mg.ml -1 to 8 mg.ml -1 , with a median of 2 mg.ml -1 . Three units adjust the concentration of dopamine on a patient-by-patient basis so that volumetric administration is equivalent to weight-referenced administration (i.e., x ml.h -1 ≅ x µg.kg -1 .min -1 ) (see Table 3 ).
Sixteen of these 23 units (70%) use weightreferenced administration (i.e., µg.kg -1 .min -1 ). The questionnaire did not seek information concerning the methods of weight determination. The remaining seven units use an absolute method of drug administration (variously µg.min -1 , mg.h -1 , or ml.h -1 of a standard concentration). However three of these seven units also use a dose conversion chart to determine µg.kg -1 .min -1 equivalency (see Table 3 ). Those units using weight-referenced administration were likely to be users of "renal-dose" dopamine (P=0.02).
Several participants offered additional unsolicited comments. Respondents from units that never use dopamine nominated noradrenaline, adrenaline and dobutamine amongst their favoured alternatives. When noradrenaline is required to achieve a desired haemodynamic target, at least three of the units which use dopamine will leave low-dose dopamine to run concurrently, variously for "renal" effects or inotropy. One small level 1 unit only ever uses inotropes under the advice of the proximate tertiary ICU pending interhospital transfer.
DISCUSSION
Dopamine is used as an inotrope at some time or other by the majority of NZ public hospital ICUs. Dopamine use per se was evenly distributed across all ICU levels, and was not associated with the level of ICU. Without any intimation of relative merit, "renaldose" dopamine is currently at least occasionally in use in many NZ ICUs, but with a moderately large variation in what is considered to be "renal-dose". The use of "renal-dose" dopamine has been found to be less likely in level 3 ICUs than in levels 1 and 2. Many potential interpretations can be placed on this finding, but given the small numbers involved, the finding should be evaluated cautiously. An observed twenty-fold difference in standard dopamine dilution supports the premise that the use of dopamine is far from standardized across NZ ICUs.
Seventy per cent of those who use dopamine do so with weight-referenced prescription and administration. A further 13% use conversion tables indicating that these ICUs also consider dopamine doses in a weight-referenced fashion. The implied precision and value of such methods are questionable 2 . Given the observed association between weight-referenced administration and use of "renal-dose" dopamine (16 of 17 units who ever use "renal-dose" dopamine also use weight-referenced administration; 16 of 19 who use weight-referenced methods are "renaldopamine" users), it may be that use of µg.kg -1 .min -1 perpetuates the use of dopamine for presumed selective renal benefits. If this is so, in the author's opinion it should be added to the list of reasons for avoiding weight-referenced administration of dopamine. It is acknowledged that the demands of paediatric critical care are different, and that weight-referenced dosing is more appropriate for children. The sole NZ paediatric ICU is amongst those who have reported use of these methods.
The body weight of any critically ill adult patient is frequently estimated rather than measured, often inaccurately 3, 4 . Therefore to select a µg-sized dose based on estimated body weight is predetermined to be associated with a variable inherent error. The methods used for weight determination have not been explored. Administering any drug in µg.kg -1 quantities implies a degree of precision, and further precision is implied by delivering this small mass of drug on a per minute basis. Furthermore, considering the large variability in plasma levels of dopamine with comparable weight-referenced rates of administration 5 , variably altered dopamine clearance in critical illness 6 , and lengthy equilibration times after alteration of dopamine infusion rate 7 , it becomes increasingly difficult to support the pretext of µg.kg -1 .min -1 administration.
Pharmacokinetic shortcomings notwithstanding, it is likely that weight-referenced administration is selected in order to facilitate titration within ranges associated with putative sequential receptor activation. However, the basis upon which this rests remains uncertain. Sequential dose-dependent activation of dopaminergic, beta and alpha adrenergic receptors by dopamine has become so accepted that standard textbooks [8] [9] [10] [11] present µg.kg -1 .min -1 dose ranges largely without any supporting references. Even when original research [12] [13] [14] [15] is examined, the origins of the oft-quoted dose ranges are not immediately apparent. It is more sensible to titrate drug administration against the observed effects in the individual patient, rather than to pursue any assumed relative adrenergic receptor activation 2 .
The varied status of respondents in this study may be perceived as a limitation. However, the stated intention was to describe the way in which dopamine infusions are actually prescribed and titrated at the bedside on a day-to-day basis in clinical Intensive Care practice throughout NZ. To that end, the registrars who are charting the infusions or the nurses who are administering them are well placed to provide the information. It is expected that the practical application of dopamine infusions will necessarily reflect the consensus view of the senior medical staff in any well run ICU. Undoubtedly there will remain some differences of opinion between individual clinicians in any given unit. However there was no stated or implied intention to explore the "unit views" as such, nor any aspects of the relative merits of dopamine per se or its increasingly improbable selective renal effects 16 .
To summarize, dopamine is commonly used in NZ ICUs, most often administered in a weightreferenced manner (i.e., µg.kg -1 .min -1 ). The standard dilution of dopamine varies widely between units. "Renal-dose" dopamine continues to be used relatively commonly in NZ ICUs, but is less likely to be in use in level 3 units when compared to levels 1 and 2. An association between weight-referenced administration and the persisting use of "renal-dose" dopamine has been shown. Taking this together with particular pharmacokinetic reservations, uncertainties regarding the weight of critically ill patients and the paucity of conclusive dose-response data for sequential receptor activation, the value of weightreferenced administration in adult patients is questioned. It has no proven clinical utility 2 and its implied precision is illusory. Absolute dosing methods with titration against observable clinical parameters are advocated 2 .
